Asymmetric dimethylarginine level as biomarkers of cardiovascular or all-cause mortality in patients with chronic kidney disease: a meta-analysis

References

• Aucella, F., et al., 2009. Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study. Atherosclerosis, 207 (2), 541–545.
   PubMed Web of Science ®Google Scholar
• Chan, N.N., and Chan, J.C., 2002. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia, 45 (12), 1609–1616.
   PubMed Web of Science ®Google Scholar
• Cheung, A.K., et al., 2000. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney international, 58 (1), 353–362.
   PubMed Web of Science ®Google Scholar
• Cooke, J.P., 2000. Does ADMA cause endothelial dysfunction? Arteriosclerosis, thrombosis, and vascular biology, 20 (9), 2032–2037.
   PubMed Web of Science ®Google Scholar
• Deneva-Koycheva, T.I., et al., 2011. Plasma asymmetric dimethylarginine levels in healthy people. Folia medica, 53 (1), 28–33.
   PubMedGoogle Scholar
• Drew, D.A., et al., 2014. Asymmetric dimethylarginine, race, and mortality in hemodialysis patients. Clinical journal of the American Society of Nephrology, 9 (8), 1426–1433.
   PubMed Web of Science ®Google Scholar
• Eiselt, J., et al., 2014. Asymmetric dimethylarginine and progression of chronic kidney disease: a one-year follow-up study. Kidney and blood pressure research, 39 (1), 50–57.
   PubMed Web of Science ®Google Scholar
• Fliser, D., et al., 2005. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. Journal of the American Society of Nephrology, 16 (8), 2456–2461.
   PubMed Web of Science ®Google Scholar
• Go, A.S., et al., 2004. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. The New England journal of medicine, 351 (13), 1296–1305.
   PubMed Web of Science ®Google Scholar
• Herzog, C.A., et al., 2011. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney international, 80 (6), 572–586.
   PubMed Web of Science ®Google Scholar
• Hill, N.R., et al., 2016. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS one, 11 (7), e0158765.
   PubMed Web of Science ®Google Scholar
• Huang, W.C., et al., 2019. Association between asymmetric dimethylarginine and in-stent restenosis tissue characteristics assessed by optical coherence tomography. International journal of cardiology, 289, 131–137.
   PubMed Web of Science ®Google Scholar
• Ignjatovic, A.M., et al., 2013. Endothelial dysfunction, inflammation and malnutrition markers as predictors of mortality in dialysis patients: multimarker approach. International urology and nephrology, 45, 1715–1724.
   PubMed Web of Science ®Google Scholar
• Koleva, D.I., et al., 2016. Pathophysiological role of adiponectin, leptin and asymmetric dimethylarginine in the process of atherosclerosis. Folia medica, 58 (4), 234–240.
   PubMedGoogle Scholar
• Landim, M.B., Casella Filho, A., and Chagas, A.C., 2009. Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis. Clinics (Sao Paulo, Brazil), 64 (5), 471–478.
   PubMed Web of Science ®Google Scholar
• Lau, J., et al., 2006. The case of the misleading funnel plot. BMJ (clinical research ed.), 333 (7568), 597–600.
   PubMed Web of Science ®Google Scholar
• Levin, A., et al., 2014. Biomarkers of inflammation, fibrosis, cardiac stretch and injury predict death but not renal replacement therapy at 1 year in a Canadian chronic kidney disease cohort. Nephrology, dialysis, transplantation, 29 (5), 1037–1047.
   PubMed Web of Science ®Google Scholar
• Lu, T.M., et al., 2011. Asymmetric dimethylarginine and clinical outcomes in chronic kidney disease. Clinical journal of the American Society of Nephrology, 6 (7), 1566–1572.
   PubMed Web of Science ®Google Scholar
• Lv, J.C., and Zhang, L.X., 2019. Prevalence and disease burden of chronic kidney disease. Advances in experimental medicine and biology, 1165, 3–15.
   PubMed Web of Science ®Google Scholar
• Malyszko, J., and Matuszkiewicz-Rowinska, J., 2018. Endothelium, asymmetric dimethylarginine, and atherosclerosis in chronic kidney disease. Polish archives of internal medicine, 128, 145–147.
   PubMedGoogle Scholar
• Rysz, J., et al., 2017. Novel biomarkers in the diagnosis of chronic kidney disease and the prediction of its outcome. International journal of molecular sciences, 18 (8), 1702.
   PubMed Web of Science ®Google Scholar
• Shafi, T., et al., 2017. Serum asymmetric and symmetric dimethylarginine and morbidity and mortality in hemodialysis patients. American journal of kidney diseases, 70 (1), 48–58.
   PubMed Web of Science ®Google Scholar
• Shi, B., et al., 2010. Circulating levels of asymmetric dimethylarginine are an independent risk factor for left ventricular hypertrophy and predict cardiovascular events in pre-dialysis patients with chronic kidney disease. European journal of internal medicine, 21 (5), 444–448.
   PubMed Web of Science ®Google Scholar
• Sibal, L., et al., 2010. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Current cardiology reviews, 6 (2), 82–90.
   PubMedGoogle Scholar
• Testa, A., et al., 2005. The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease. Journal of hypertension, 23 (10), 1825–1830.
   PubMed Web of Science ®Google Scholar
• Thomas, B., et al., 2015. Maintenance dialysis throughout the world in years 1990 and 2010. Journal of the American Society of Nephrology, 26 (11), 2621–2633.
   PubMed Web of Science ®Google Scholar
• Ueda, S., et al., 2009. Involvement of asymmetric dimethylarginine (ADMA) in glomerular capillary loss and sclerosis in a rat model of chronic kidney disease (CKD). Life sciences, 84 (23–24), 853–856.
   PubMed Web of Science ®Google Scholar
• Vallance, P., and Leiper, J., 2004. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arteriosclerosis, thrombosis, and vascular biology, 24 (6), 1023–1030.
   PubMed Web of Science ®Google Scholar
• Vallance, P., et al., 1992. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet (London, England), 339 (8793), 572–575.
   PubMed Web of Science ®Google Scholar
• Wang, F., et al., 2018. Association of circulating levels of ADMA with carotid intima-media thickness in patients with CKD: a systematic review and meta-analysis. Kidney & blood pressure research, 43 (1), 25–33.
   PubMed Web of Science ®Google Scholar
• Wells, G., Shea, B., O’Connell, D., Peterson, J., Welch, V., Losos, M., Tugwell, P. 2015. The Newcastle–Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp [Accessed 18 March 2021].
   Google Scholar
• Young, J.M., et al., 2009. Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clinical journal of the American Society of Nephrology, 4 (6), 1115–1120.
   PubMed Web of Science ®Google Scholar
• Zhou, S., et al., 2017. Asymmetric dimethylarginine and all-cause mortality: a systematic review and meta-analysis. Scientific reports, 7, 44692.
   PubMed Web of Science ®Google Scholar
• Zoccali, C., et al., 2001. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet (London, England), 358 (9299), 2113–2117.
   PubMed Web of Science ®Google Scholar